WO2006021692A1 - Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif - Google Patents
Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif Download PDFInfo
- Publication number
- WO2006021692A1 WO2006021692A1 PCT/FR2005/002092 FR2005002092W WO2006021692A1 WO 2006021692 A1 WO2006021692 A1 WO 2006021692A1 FR 2005002092 W FR2005002092 W FR 2005002092W WO 2006021692 A1 WO2006021692 A1 WO 2006021692A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- matrix tablet
- tablet
- tablets
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
Definitions
- the present invention relates to a pharmaceutical composition in tablet form, containing an active ingredient, used for administration once a day.
- the conventional sustained-release dosage forms are hardly suitable for certain active principles which have an absorption window in the upper parts of the gastrointestinal tract, that is to say which are absorbed in the stomach, the upper parts. small intestine, duodenum, jejunum and ilium, and less or less at the colonic level. Indeed, the conventional administration unit releases the active substance throughout its passage in the gastrointestinal tract and not only in the part where the absorption of the active ingredient is maximum.
- the present invention relates to a pharmaceutical composition in tablet form containing an active ingredient, used for administration once a day, overcoming the disadvantages mentioned above.
- the invention is characterized in that in contact with the gastric fluid, the pharmaceutical composition rapidly increases its volume. It is indeed clearly advantageous that this composition increases its volume not only considerably but also very rapidly, as soon as it comes into contact with the gastric fluid. This makes it possible to ensure a longer residence time of this pharmaceutical composition in the stomach, to avoid premature gastric emptying and thus to ensure that most of the active ingredient contained in the pharmaceutical composition is released and absorbed. in the portion of the gastrointestinal tract where the absorption capacity is highest.
- An object of the invention is a pharmaceutical composition under form of a matrix tablet, comprising an active ingredient, and allowing a prolonged release of the latter, which after fifteen minutes in contact with a representative medium of the gastric fluid rapidly increases in volume, with a swelling rate of at least 200 %, more particularly at least 250%.
- matrix tablet is meant a pharmaceutical composition for oral administration containing an active substance dispersed uniformly in one or more suitable excipients which, after compression, allow the formation of a matrix capable of controlling the release of the active principle.
- representative medium of the gastric fluid is meant a 0.01 M aqueous solution of hydrochloric acid and 0.1 M sodium chloride at 37 ° C.
- the rate of swelling of the tablets is determined by measuring the thickness and the diameter of the dry tablet and the tablet remained fifteen minutes immersed in the representative medium of the gastric fluid and using a suitable measuring instrument.
- the degree of swelling (in percent) can thus be expressed in terms of thickness, diameter or volume, according to the following formulas:
- Vto Volume of the tablet at TO
- Seen 5 Volume of the tablet at 15 minutes. the volume of the tablet being calculated according to the following formula
- D is the tablet diameter
- e is the thickness of the tablet wafer
- h is the half difference between the total tablet thickness and the wafer thickness
- R is the tablet radius of curvature.
- the pharmaceutical composition is in the form of a single-phase matrix tablet.
- the pharmaceutical composition is in the form of a matrix tablet having at least two phases.
- the pharmaceutical composition may comprise one or more active ingredients in one or more phases.
- the pharmaceutical composition will more particularly comprise one or two active subtances.
- phase is meant a homogeneous mixture of one or more excipients, in the form of a powder or granule, which may contain an active ingredient.
- a pharmaceutical composition according to the invention comprising two or more phases may be in the form of a multi-layer tablet (bilayer, tri-layer, etc.), more particularly a bilayer, or in the form of a core. covered with one or more phases.
- the invention consists of a pharmaceutical composition in the form of a gastric residence matrix tablet comprising an active ingredient, and at least one phase containing, at least, as excipients: a) povidone and / or polyvinyl acetate in proportions ranging from 30 to 80% by weight of the phase,
- crospovidone may be replaced or combined with another super-disintegrant such as low-substituted hydroxypropylcellulose (L-HPC), sodium carboxymethyl starch and / or croscarmellose sodium.
- L-HPC low-substituted hydroxypropylcellulose
- sodium carboxymethyl starch sodium carboxymethyl starch
- croscarmellose sodium another super-disintegrant
- the matrix tablet according to the invention has the advantage of swelling very quickly in contact with gastric fluids. Indeed, the presence of excipients a), b) and c) in the proportions according to the invention makes it possible to obtain a synergy of swelling. The tablet could thus reside for several hours in the stomach.
- the matrix compound comprises at least two phases, one or more of the phases may comprise an active ingredient.
- each phase may have an identical or different composition in excipients of another phase, it being understood that at least one of the phases comprises the excipients a), b) and c) in the proportions as indicated according to the invention.
- one of the phases does not include the excipients a), b) and c), each in the proportions as indicated according to the invention, the skilled person can determine its composition according to the biopharmaceutical requirements, such as control release of the active ingredient, increased swelling rate.
- povidone and polyvinyl acetate excipients or the povidone / polyvinyl acetate mixture are commercially available or, more particularly, the mixture is chosen from those sold under the name Kollidon® SR.
- the povidone and / or the polyvinyl acetate are in an amount ranging from 30 to 80% by weight of the phase containing it and more particularly from 30 to 65%.
- Crospovidone is a crosslinked homopolymer of ⁇ -vinyl-2-pyrrolidinone of molecular weight greater than 1,000,000DA. This polymer belongs to the category of super-disintegrants, able to quickly and intensively capture the surrounding liquid.
- crospovidone sold commercially under the name Kollidon® CL (BASF) or Plasdone® XL (ISP).
- Hydroxypropylcellulose is a low-substituted hydroxypropyl ether of cellulose, insoluble in water and alcohols but capable of swelling in these solvents.
- L-HPC LH-11 grade provided by Shin Etsu.
- Sodium carboxymethyl starch or sodium starch glycolate is the sodium salt of a carboxymethyl starch ether. There are three grades, A, B and C, which differs in sodium content. By way of example, mention may be made of sodium starch glycolate sold under the trade name Primojel® (Avebe) or Explotab® (JRS Pharma).
- Croscarmellose sodium is a cellulosic polymer obtained by crosslinking carmellose sodium.
- Ad-Di-Sol® Ad-Di-Sol®
- Crospovidone or super-disintegrants such as low-substituted hydroxypropylcellulose, sodium carboxymethyl starch or sodium starch glycolate, croscarmellose sodium, are present in an amount ranging from 5 to 25% by weight of the phase containing them and more particularly of
- the carbomer is a polymer of acrylic acid crosslinked with an allyl ether of sucrose or pentaerythritol having a very high molecular weight (of the order of one million).
- Carbopol® 974 or Carbopol® 71G NOVEON
- Carbopol® 71G which makes it possible to obtain aqueous dispersions having a viscosity of between 4000 and 11000 cps (dispersion at 0.5%).
- the carbomer is in the tablet or in a phase in proportions in an amount ranging from 5 to 40% by weight respectively of the tablet or the phase and more particularly from 10 to 35%.
- the excipients a), b) and c) are respectively in amounts of 40 to 70% for povidone and / or polyvinyl acetate, 10 to 20% for crospovidone and 10 to 30% for the carbomer.
- the tablet may also include any suitable excipient necessary for the manufacture of the tablet, such as:
- soluble or insoluble diluents microcrystalline cellulose, lactose, mannitol, dicalcium phosphate, etc.
- insoluble diluents in an amount ranging from 5 to 30% by weight of the phase containing it;
- lubricants magnesium stearate, talc, hydrogenated castor oil, PEG 6000, glycerol behenate, stearic acid, etc.
- flow agents colloidal silica, precipitated silica, etc.
- compositions according to the invention may for example be useful for benzamides and ⁇ 1 -antagonists, as well as the following active ingredients: captopril, furosemide, ursodesoxycholic acid, amoxicillin, (+) - ⁇ - aminomethyl-2-methoxysulfonamidobenzenemethanol (disclosed in patent application EP 842 148 to Example 3.6) or 3'- (2-amino-hydroxyethyl) -4'-fluoromethanesulfonanilide (NS 49).
- the benzamides are in particular metoclopramide, veralipride, alizapride, and clébopride, especially in amisulpride, tiapride, sulpiride and their salts.
- ⁇ 1 -antagonists are in particular terazosin and alfuzosin and their salts, in particular alfuzosin hydrochloride. They are intended in particular for the treatment of benign prostatic hypertrophy.
- Captopril is used especially for the treatment of hypertension, furosemide as a diuretic, arnoxicillin and its salts as an antibiotic, and ursodesoxycholic acid and its salts is used for the treatment of cholelithiases, hepatic disorders and syphilis.
- Benzamides, ⁇ 1-antagonists are also covered, including their mixtures, in particular their racemic mixtures, but also their salts.
- active ingredients which are more particularly suitable for the compositions according to the invention, mention may be made of amisulpride (D) -tartrate, (S) - (-)
- the amount of active ingredient in the pharmaceutical composition is generally from 0.1 mg to 200 mg.
- the tablets of the invention can be produced by direct compression of a mixture of powders or by granulation and compression using the usual production technologies.
- the chosen compression format can be optimized according to the general knowledge of the skilled person.
- the working compression force varies between 500 DaN and 3000 DaN so as to obtain tablets with a tensile strength that allows them to be handled and administered without any problem (between 80 and 300N for 10R10 mm tablets, for example) . Obtained, according to the methods to be described in more detail in the examples, mono tablets, or at least two phases having a shape that allows easy administration and swallowing.
- each phase of the tablet may have a different thickness ranging from 1 to 8 mm, but preferably from 2 mm to 6 mm. These dimensions may vary depending on the compression format.
- Example 1 Preparation of a monolayer tablet comprising 10 mg of alfuzosin hydrochloride
- the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression machine.
- the rate of swelling of the tablets is determined by measuring the thickness and the diameter of the dry tablet and the tablet which has been left for 15 minutes immersed in gastric liquid at 37 ° C. (0.01 M HCl + 0.1 M NaCl), and this using a suitable measuring instrument.
- the swelling ratio is 80% by thickness and 25% by diameter, ie about 200% by volume.
- the release profile an active ingredient in the gastric medium (pH2 + 0.1 M NaCl) obtained with this formulation is a profile of order 0 is: - 10 to 20% released in 1 hour.
- the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression machine. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® mixer. The mixture flows freely and facilitates the filling of the compression chamber.
- the swelling rate of the tablets is determined by the method described above.
- the swelling is 80% in thickness and 30% in diameter, ie about 300% by volume.
- the release profile an active ingredient in the gastric medium (pH2 + 0.1 M NaCl) obtained with this formulation is a profile of order 0 is: - 10 to 20% released in 1 hour.
- Example 3 Preparation of a bi-layer tablet comprising 10 mg of alfuzosin hydrochloride
- the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
- the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 300% by volume.
- the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula ® inverting mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
- the swelling rate of the tablets is determined by the method described above in Example 1. In this example, the swelling is 350% by volume.
- Example 5 Preparation of a 500 mg two-layer tablet comprising 10 mg of alfuzosin hydrochloride
- the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
- Flow of the mixture ⁇ 10 seconds per 100g of mixture.
- Hardness of the tablets 150N. Mass of the tablets: 500 mg. Tablet size: 12R12 mm.
- the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 360% by volume.
- the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
- the swelling rate of the tablets is determined by the method described above. In this example, the swelling is. 2Z0 ._% by volume.
- Example 7 Preparation of a bi-layer tablet comprising 10 mg of alfuzosin hydrochloride
- the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
- the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 300% by volume.
- the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press.
- the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 300% by volume.
- Examples 9 and 10 below show single-layer monosaccharide tablet compositions. These compositions can be used as a swelling placebo layer in the manufacture of multilayer tablets. It is also possible to incorporate the active ingredient in these compositions, for example at a height of 10 mg, in order to obtain a pharmaceutical composition according to the invention.
- Example 9 Preparation of a 500 mg monolayer placebo tablet.
- the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press.
- the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 340% by volume.
- Example 10 Preparation of a 500 mg monolayer placebo tablet.
- the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
- the swelling rate of the tablets is determined by the method described above. In this example, the swelling is 470% by volume.
- Example 11 Preparation of a tri-layer tablet of 700 mg containing 10 mg of alfuzosin hydrochloride.
- the tablets described in this example are obtained by direct compression using a Forgerais OA alternative compression press. - Beforehand, all the excipients are sieved (1 mm grid) and then mixed using a Turbula® inversion mixer. The mixture flows freely, thus facilitating the filling of the compression chamber.
- the swelling rate of the tablets is determined by the method described above.
- the swelling is 104% in thickness, 41% in width and 36% in length.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007526512A JP5048492B2 (ja) | 2004-08-19 | 2005-08-17 | 活性成分を含有する胃貯留錠の形態の薬学的組成物 |
BRPI0514532-5A BRPI0514532A (pt) | 2004-08-19 | 2005-08-17 | composição farmacêutica sob a forma de comprimido com permanência gástrica, contendo um princìpio ativo |
EA200700217A EA012981B1 (ru) | 2004-08-19 | 2005-08-17 | Фармацевтическая композиция в форме таблетки для нахождения в желудке, содержащая активное вещество |
CA2577361A CA2577361C (fr) | 2004-08-19 | 2005-08-17 | Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif |
MX2007001957A MX2007001957A (es) | 2004-08-19 | 2005-08-17 | Composicion farmaceutica en forma de comprimido de residencia gastrica que contiene un principio activo. |
EP05798249A EP1781295A1 (fr) | 2004-08-19 | 2005-08-17 | Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif |
CN2005800311527A CN101022808B (zh) | 2004-08-19 | 2005-08-17 | 含有活性组分的胃滞留片剂的药物组合物 |
AU2005276307A AU2005276307B2 (en) | 2004-08-19 | 2005-08-17 | Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle |
NZ553673A NZ553673A (en) | 2004-08-19 | 2005-08-17 | Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle |
IL181150A IL181150A0 (en) | 2004-08-19 | 2007-02-04 | Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle |
US11/675,712 US20070190140A1 (en) | 2004-08-19 | 2007-02-16 | Pharmaceutical Composition in the Form of a Gastric-Resident Tablet Containing an Active Principle |
ZA2007/01443A ZA200701443B (en) | 2004-08-19 | 2007-02-19 | Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle |
NO20071315A NO20071315L (no) | 2004-08-19 | 2007-03-09 | Farmasoytisk preparat i form av en tablett inneholdende et aktivt prinsipp for opphold i magen. |
HK08101572.6A HK1112575A1 (en) | 2004-08-19 | 2008-02-13 | Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0408986 | 2004-08-19 | ||
FR0408986A FR2874325B1 (fr) | 2004-08-19 | 2004-08-19 | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/675,712 Continuation US20070190140A1 (en) | 2004-08-19 | 2007-02-16 | Pharmaceutical Composition in the Form of a Gastric-Resident Tablet Containing an Active Principle |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006021692A1 true WO2006021692A1 (fr) | 2006-03-02 |
WO2006021692A8 WO2006021692A8 (fr) | 2007-04-12 |
Family
ID=34950702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/002092 WO2006021692A1 (fr) | 2004-08-19 | 2005-08-17 | Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif |
Country Status (23)
Country | Link |
---|---|
US (1) | US20070190140A1 (fr) |
EP (1) | EP1781295A1 (fr) |
JP (1) | JP5048492B2 (fr) |
KR (1) | KR20070046124A (fr) |
CN (1) | CN101022808B (fr) |
AR (1) | AR050696A1 (fr) |
AU (1) | AU2005276307B2 (fr) |
BR (1) | BRPI0514532A (fr) |
CA (1) | CA2577361C (fr) |
EA (1) | EA012981B1 (fr) |
FR (1) | FR2874325B1 (fr) |
HK (1) | HK1112575A1 (fr) |
IL (1) | IL181150A0 (fr) |
MA (1) | MA28862B1 (fr) |
MX (1) | MX2007001957A (fr) |
MY (1) | MY145832A (fr) |
NO (1) | NO20071315L (fr) |
NZ (1) | NZ553673A (fr) |
PE (1) | PE20060639A1 (fr) |
TW (1) | TWI357329B (fr) |
UY (1) | UY29073A1 (fr) |
WO (1) | WO2006021692A1 (fr) |
ZA (1) | ZA200701443B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008280251A (ja) * | 2007-05-08 | 2008-11-20 | Shin Etsu Chem Co Ltd | 多層錠及びその製造方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9205094B2 (en) | 2006-12-22 | 2015-12-08 | Ironwood Pharmaceuticals, Inc. | Compositions comprising bile acid sequestrants for treating esophageal disorders |
WO2008102235A1 (fr) * | 2007-02-20 | 2008-08-28 | Aurobindo Pharma Limited | Formulations d'alfuzosine à libération contrôlée |
CN102076215A (zh) | 2008-06-30 | 2011-05-25 | 托卡根公司 | 5-氟胞嘧啶制剂及其用途 |
WO2011102506A1 (fr) * | 2010-02-22 | 2011-08-25 | 第一三共株式会社 | Préparation solide à libération prolongée pour usage oral |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US10569071B2 (en) | 2015-08-31 | 2020-02-25 | Ethicon Llc | Medicant eluting adjuncts and methods of using medicant eluting adjuncts |
US10245034B2 (en) * | 2015-08-31 | 2019-04-02 | Ethicon Llc | Inducing tissue adhesions using surgical adjuncts and medicants |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1546448A (en) * | 1975-03-17 | 1979-05-23 | Hoffmann La Roche | Sustained-release formulations |
EP0486863A1 (fr) * | 1990-11-17 | 1992-05-27 | Bayer Ag | Compositions antiacides à séjour gastrique prolongé |
WO1998008515A1 (fr) * | 1996-08-29 | 1998-03-05 | Synthelabo | Comprime a liberation controlee de chlorhydrate d'alfuzosine |
WO1998051408A1 (fr) * | 1997-05-13 | 1998-11-19 | Purdue Research Foundation | Composites d'hydrogel et composites d'hydrogel superporeux avec action gonflante rapide, resistance mecanique elevee et proprietes superabsorbantes |
WO1999061004A1 (fr) * | 1998-05-28 | 1999-12-02 | Medical Research Institute | Acide lipoique a liberation lente |
FR2784583A1 (fr) * | 1998-10-16 | 2000-04-21 | Synthelabo | Composition pharmaceutique a residence gastrique et a liberation controlee |
WO2002000213A1 (fr) * | 2000-06-23 | 2002-01-03 | Teva Pharmaceutical Industries Ltd. | Composition a expansion rapide pour retention gastrique et liberation regulee d'agents therapeutiques, et formes posologiques renfermant cette composition |
WO2002000204A1 (fr) * | 2000-06-23 | 2002-01-03 | Teva Pharmaceutical Industries Ltd. | Compositions et forme posologique pour liberation gastrique retardee d'alendronate et/ou d'autres bis-phosphonates |
WO2002062321A2 (fr) * | 2001-02-08 | 2002-08-15 | Ellipse Pharmaceuticals | Procede de fabrication d'un comprime flottant incluant de l'alfuzosine |
WO2002070021A1 (fr) * | 2001-03-05 | 2002-09-12 | Teva Pharmaceutical Industries Ltd. | Composition d'administration par voie gastrique d'agents anticancereux et methodes de traitement par inhibition de cellules cancereuses les utilisant |
WO2003011255A1 (fr) * | 2001-07-04 | 2003-02-13 | Sun Pharmaceutical Industries Limited | Systeme d'administration regulee de medicament a retention gastrique |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
US6632451B2 (en) * | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
DE10014588A1 (de) * | 2000-03-27 | 2001-10-04 | Basf Ag | Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung |
US6881424B1 (en) * | 2000-09-05 | 2005-04-19 | Mionix Corporation | Highly acidic metalated organic acid |
US20040219186A1 (en) * | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
US20030215526A1 (en) * | 2002-03-08 | 2003-11-20 | Scott Stofik | Stable formulations of angiotensin converting enzyme (ACE) inhibitors |
-
2004
- 2004-08-19 FR FR0408986A patent/FR2874325B1/fr not_active Expired - Fee Related
-
2005
- 2005-08-04 PE PE2005000906A patent/PE20060639A1/es not_active Application Discontinuation
- 2005-08-16 AR ARP050103428A patent/AR050696A1/es not_active Application Discontinuation
- 2005-08-17 MX MX2007001957A patent/MX2007001957A/es active IP Right Grant
- 2005-08-17 WO PCT/FR2005/002092 patent/WO2006021692A1/fr active Application Filing
- 2005-08-17 UY UY29073A patent/UY29073A1/es not_active Application Discontinuation
- 2005-08-17 BR BRPI0514532-5A patent/BRPI0514532A/pt not_active IP Right Cessation
- 2005-08-17 MY MYPI20053859A patent/MY145832A/en unknown
- 2005-08-17 JP JP2007526512A patent/JP5048492B2/ja not_active Expired - Fee Related
- 2005-08-17 NZ NZ553673A patent/NZ553673A/en not_active IP Right Cessation
- 2005-08-17 CN CN2005800311527A patent/CN101022808B/zh not_active Expired - Fee Related
- 2005-08-17 CA CA2577361A patent/CA2577361C/fr not_active Expired - Fee Related
- 2005-08-17 EP EP05798249A patent/EP1781295A1/fr not_active Withdrawn
- 2005-08-17 EA EA200700217A patent/EA012981B1/ru not_active IP Right Cessation
- 2005-08-17 KR KR1020077003897A patent/KR20070046124A/ko not_active Application Discontinuation
- 2005-08-17 AU AU2005276307A patent/AU2005276307B2/en not_active Ceased
- 2005-08-18 TW TW094128210A patent/TWI357329B/zh not_active IP Right Cessation
-
2007
- 2007-02-04 IL IL181150A patent/IL181150A0/en unknown
- 2007-02-16 US US11/675,712 patent/US20070190140A1/en not_active Abandoned
- 2007-02-19 ZA ZA2007/01443A patent/ZA200701443B/en unknown
- 2007-03-09 NO NO20071315A patent/NO20071315L/no not_active Application Discontinuation
- 2007-03-14 MA MA29756A patent/MA28862B1/fr unknown
-
2008
- 2008-02-13 HK HK08101572.6A patent/HK1112575A1/xx not_active IP Right Cessation
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1546448A (en) * | 1975-03-17 | 1979-05-23 | Hoffmann La Roche | Sustained-release formulations |
EP0486863A1 (fr) * | 1990-11-17 | 1992-05-27 | Bayer Ag | Compositions antiacides à séjour gastrique prolongé |
WO1998008515A1 (fr) * | 1996-08-29 | 1998-03-05 | Synthelabo | Comprime a liberation controlee de chlorhydrate d'alfuzosine |
WO1998051408A1 (fr) * | 1997-05-13 | 1998-11-19 | Purdue Research Foundation | Composites d'hydrogel et composites d'hydrogel superporeux avec action gonflante rapide, resistance mecanique elevee et proprietes superabsorbantes |
WO1999061004A1 (fr) * | 1998-05-28 | 1999-12-02 | Medical Research Institute | Acide lipoique a liberation lente |
FR2784583A1 (fr) * | 1998-10-16 | 2000-04-21 | Synthelabo | Composition pharmaceutique a residence gastrique et a liberation controlee |
WO2002000213A1 (fr) * | 2000-06-23 | 2002-01-03 | Teva Pharmaceutical Industries Ltd. | Composition a expansion rapide pour retention gastrique et liberation regulee d'agents therapeutiques, et formes posologiques renfermant cette composition |
WO2002000204A1 (fr) * | 2000-06-23 | 2002-01-03 | Teva Pharmaceutical Industries Ltd. | Compositions et forme posologique pour liberation gastrique retardee d'alendronate et/ou d'autres bis-phosphonates |
WO2002062321A2 (fr) * | 2001-02-08 | 2002-08-15 | Ellipse Pharmaceuticals | Procede de fabrication d'un comprime flottant incluant de l'alfuzosine |
WO2002070021A1 (fr) * | 2001-03-05 | 2002-09-12 | Teva Pharmaceutical Industries Ltd. | Composition d'administration par voie gastrique d'agents anticancereux et methodes de traitement par inhibition de cellules cancereuses les utilisant |
WO2003011255A1 (fr) * | 2001-07-04 | 2003-02-13 | Sun Pharmaceutical Industries Limited | Systeme d'administration regulee de medicament a retention gastrique |
Non-Patent Citations (1)
Title |
---|
See also references of EP1781295A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008280251A (ja) * | 2007-05-08 | 2008-11-20 | Shin Etsu Chem Co Ltd | 多層錠及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20070046124A (ko) | 2007-05-02 |
CN101022808B (zh) | 2013-05-29 |
AR050696A1 (es) | 2006-11-15 |
WO2006021692A8 (fr) | 2007-04-12 |
FR2874325A1 (fr) | 2006-02-24 |
EA012981B1 (ru) | 2010-02-26 |
US20070190140A1 (en) | 2007-08-16 |
JP2008509973A (ja) | 2008-04-03 |
FR2874325B1 (fr) | 2006-10-20 |
TWI357329B (en) | 2012-02-01 |
ZA200701443B (en) | 2008-05-25 |
NZ553673A (en) | 2010-10-29 |
EP1781295A1 (fr) | 2007-05-09 |
CA2577361C (fr) | 2013-10-01 |
AU2005276307A1 (en) | 2006-03-02 |
MY145832A (en) | 2012-04-30 |
NO20071315L (no) | 2007-03-09 |
CN101022808A (zh) | 2007-08-22 |
IL181150A0 (en) | 2007-07-04 |
EA200700217A1 (ru) | 2007-08-31 |
CA2577361A1 (fr) | 2006-03-02 |
BRPI0514532A (pt) | 2008-06-17 |
JP5048492B2 (ja) | 2012-10-17 |
TW200618802A (en) | 2006-06-16 |
MX2007001957A (es) | 2007-04-25 |
UY29073A1 (es) | 2006-03-31 |
AU2005276307B2 (en) | 2011-02-24 |
HK1112575A1 (en) | 2008-09-12 |
PE20060639A1 (es) | 2006-07-20 |
MA28862B1 (fr) | 2007-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE1011045A3 (fr) | Compositions pharmaceutiques pour la liberation controlee de substances actives. | |
CA2219475C (fr) | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation | |
CA2577361C (fr) | Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif | |
CA2273420C (fr) | Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale | |
EP1631263B1 (fr) | Comprime orodispersible multicouche | |
FR2855756A1 (fr) | Comprime orodispersible multicouche | |
CA2721232C (fr) | Forme orale solide dotee d'un double profil de liberation comprenant des multiparticules | |
FR2850576A1 (fr) | Composition comprenant un melange de principes actifs, et procede de preparation | |
BE1011837A5 (fr) | Nouvelle composition de balsalazide. | |
MX2007001973A (es) | Extractor de jugo con contrapeso operativamente acoplado con un eje de levas. | |
WO2001051033A1 (fr) | Compositions pharmaceutiques solides pour la liberation controlee de substances actives | |
BE1000732A5 (fr) | Compositions pharmaceutiques a liberation prolongee. | |
BE1015413A6 (fr) | Systeme de delivrance orale controlee d'un medicament. | |
EP1512394A1 (fr) | Composition universelle à libération controlée comprenant du chitosane | |
EP1265614B1 (fr) | Nouvelle forme galenique orale a liberation prolongee de la molsidomine | |
EP1904037A1 (fr) | Formulation a liberation prolongee de principes actifs presentant une solubilite dependante du ph | |
WO2003057198A1 (fr) | Compositions pharmaceutiques a liberation modifiee | |
WO2020239645A1 (fr) | Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles | |
EP3082791A1 (fr) | Compositions pharmaceutiques orales à rétention gastrique | |
WO2000025749A9 (fr) | Utilisation de gommes xanthanes pour la preparation de compositions pharmaceutiques | |
WO1996004892A1 (fr) | Nouvelles compositions contenant de la cimetidine et associations en derivant | |
WO2003061647A1 (fr) | Composition pharmaceutique orodispersible de 2-({2-methoxy-2-[3- (trifluoromethyl) phenyl]ethyl}amino) ethyl-4-(2-{[2-(9h- fluoren-9-yl)acetyl] amino}ethyl)benzoate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200700217 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005798249 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 181150 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2007000096 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/001957 Country of ref document: MX Ref document number: 11675712 Country of ref document: US Ref document number: 1020077003897 Country of ref document: KR Ref document number: 12007500396 Country of ref document: PH Ref document number: 2007526512 Country of ref document: JP Ref document number: 2577361 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007/01443 Country of ref document: ZA Ref document number: 07016432 Country of ref document: CO Ref document number: 200701443 Country of ref document: ZA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 633/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 553673 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005276307 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580031152.7 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2005276307 Country of ref document: AU Date of ref document: 20050817 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005276307 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005798249 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11675712 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0514532 Country of ref document: BR |